Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Wednesday, July 26th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Wednesday, July, 26th. The company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $2.11 by $0.45. The business earned $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences's revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the company posted $3.08 earnings per share. View Gilead Sciences' Earnings History.

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Gilead Sciences.

25 brokerages have issued 1 year price objectives for Gilead Sciences' shares. Their predictions range from $65.50 to $95.00. On average, they expect Gilead Sciences' share price to reach $80.75 in the next year. View Analyst Ratings for Gilead Sciences.

Here are some recent quotes from research analysts about Gilead Sciences stock:

• 1. According to Zacks Investment Research, "Gilead reported better-than-expected results for the second quarter driven by positive trends in the non-HCV business and improved results from HCV business due to rapid uptake of Epclusa. The HCV franchise was boosted by the FDA approval of Vosevi. HCV patient starts in the first half were better than expectations but should see a gradual decline in the second half due to increased competition. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU, which now represent 51% of total prescription volume. Genvoya is now the company’s bestselling HIV product with a treatment-naïve patient share of 41%. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should further boost sales. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which will impact sales. Shares of the company have underperformed the industry." (7/28/2017)
• 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
• 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
• 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Gilead Sciences saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 16,844,547 shares, an increase of 25.9% from the July 14th total of 13,378,379 shares. Based on an average daily trading volume, of 9,066,173 shares, the short-interest ratio is currently 1.9 days. Currently, 1.3% of the shares of the company are short sold.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene Corporation (CELG), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), Kite Pharma (KITE), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH) and China Biologic Products (CBPO).

Gilead Sciences' management team includes the folowing people:

• John C. Martin Ph.D., Executive Chairman of the Board
• John F. Milligan Ph.D., Chief Executive Officer, Director
• Robin L. Washington, Chief Financial Officer, Executive Vice President
• Kevin B. Young, Chief Operating Officer
• Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
• James R. Meyers, Executive Vice President - Worldwide Commercial Operations
• John F. Cogan Jr. Ph.D., Lead Independent Director
• Kelly A. Kramer, Independent Director
• Kevin E. Lofton, Independent Director

Gilead Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Vanguard Group Inc. (7.11%), State Street Corp (4.45%), Bank of New York Mellon Corp (2.36%), FMR LLC (1.76%) and Capital Research Global Investors (1.40%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Capital Research Global Investors, Los Angeles Capital Management & Equity Research Inc., State Street Corp, American Century Companies Inc., AJO LP, Thrivent Financial For Lutherans and Nordea Investment Management AB. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan and Kevin E Lofton. View Insider Buying and Selling for Gilead Sciences.

Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., The Manufacturers Life Insurance Company , BlackRock Inc., Pioneer Investment Management Inc., Janus Henderson Group PLC, Neuberger Berman Group LLC and Harbour Capital Advisors LLC. View Insider Buying and Selling for Gilead Sciences.

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Gilead Sciences stock can currently be purchased for approximately $73.34.